Heterocyclic cyclopamine analogs and methods of use thereof

• US 8,426,436 B2
• Filed: 06/24/2011
• Issued: 04/23/2013
• Est. Priority Date: 03/07/2007
• Status: Expired due to Fees

• Current Assignee: Royalty Security, LLC
• Original Assignee: Infinity Discovery, Inc. (Infinity Pharmaceuticals, Inc.)
• Inventors: Castro, Alfredo C., Grogan, Michael J., Tremblay, Martin
• Primary Examiner(s): Aulakh, Charanjit
• Application Number:
  US13/168,590
• Publication Number:
  US 20120065218A1
• Time in Patent Office: 669 Days
• Field of Search: 514/278, 514/279, 546/15, 546/36
• US Class Current: 514/278
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 491/14 Ortho-condensed systems
• CPC Class Codes: C07D 513/14 Ortho-condensed systems

Abstract

The present invention relates to steroidal alkaloids that can be used in the treatment of hedgehog pathway related disorders, particularly cancer.

Claims

1. A compound of the formula:

21. A method of inhibiting activation of a hedgehog pathway in a patient diagnosed with a hyperproliferative disorder, comprising administering to the patient a compound, or a pharmaceutically acceptable salt thereof, as claimed in claim 1 in an amount sufficient to reduce the activation of the hedgehog pathway in a cell of the patient.

22. The method of claim 21, wherein said hyper proliferative disorder is cancer.

23. A method of antagonizing the hedgehog pathway in a subject, the method comprising administering to the subject an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed in claim 1.

2. A pharmaceutical composition comprising a compound of the formula:

3. A method of treating cancer, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the formula:

4. The method of claim 3, wherein the cancer is selected from the group consisting of acute lymphocytic leukemia, basal cell carcinoma, breast cancer, chondrosarcoma, chronic lymphocytic leukemia, chronic myeloid leukemia, colon cancer, esophageal cancer, gastric cancer, glioma, hepatocellular cancer, lung cancer, medulloblastoma, multiple myeloma, non-Hodgkin'"'"'s type lymphoma, osteogenic sarcoma, ovarian cancer, pancreatic cancer, and prostate cancer.

5. The method of claim 3, wherein the cancer is pancreatic cancer.

6. The method of claim 3, wherein the cancer is chondrosarcoma.

7. The method of claim 3, wherein the cancer is lung cancer.

8. The method of claim 7, wherein the lung cancer selected from the group consisting of small cell lung cancer and non-small cell lung cancer.

9. The method of claim 3, wherein the cancer is basal cell carcinoma.

10. The method of claim 3, wherein the cancer is medulloblastoma.

11. The method of claim 3, wherein the cancer is ovarian cancer.

12. The method according to claim 3, wherein the cancer is osteogenic sarcoma.

13. The method of claim 3, wherein the cancer is selected from the group consisting of acute lymphocytic leukemia, acute myelocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin'"'"'s disease, leukemia, multiple myeloma, myelodysplastic syndrome, and non-Hodgkin'"'"'s type lymphoma.

14. The method of claim 3, wherein the cancer is selected from the group consisting of acute lymphocytic leukemia, acute myelocytic leukemia, chronic myelocytic leukemia, and chronic lymphocytic leukemia.

15. The method of claim 3, wherein the compound or pharmaceutically acceptable salt thereof is used in combination with one or more chemotherapeutic or other anti-cancer agent.

16. The method of claim 15, wherein the other anti-cancer agent is radiation.

17. The method of claim 3, wherein the compound is administered locally to a tumor.

18. The method of claim 3, wherein the compound is administered systemically.

19. The method of claim 3, wherein the mode of administration of said compound is inhalation, oral, intravenous, sublingual, ocular, transdermal, rectal, vaginal, topical, intramuscular, intraperitoneal, epidural, subcutaneous, buccal, or nasal.

20. The method of claim 19, wherein the mode of administration is oral, intravenous, or topical.